Imugene (ASX:IMU) has announced that a bile tract cancer patient in its Phase 1 MAST trial remains a complete response, now surpassing more than two years in remission. …
Immugene says bile tract cancer patient maintains complete response in MAST study
November 5, 2024 Australian Biotech
Latest Video
New Stories
-
AusBiotech and Life Sciences Western Australia sign first-ever MOU
November 7, 2024 - - Australian Biotech -
The solution simply gives some certainty to submissions that had none
November 7, 2024 - - Latest News -
Rare Cancers Australia set to launch the 2025 Kosi Challenge
November 7, 2024 - - Latest News -
'The fight is not over until this is all resolved, but seeing the system start to move is a great first step'
November 7, 2024 - - Latest News -
PBAC 'directed' to meet for another full meeting in May
November 6, 2024 - - Latest News -
Doctors in Australia lead Phase 3 theranostics study targeting advanced prostate cancer
November 6, 2024 - - Australian Biotech -
Scope of practice final report triggers debate over recommendations for reform
November 6, 2024 - - Latest News